The favorable prognostic value of PDIA3 in ESCC implies that ESCC patients with high expression of PDIA3 may be more sensitive to chemotherapy such as paclitaxel, but further studies are warranted. This evidence concerns the gene PDIA3 and esophageal squamous cell carcinoma.